{ "docId": "019dd923-622c-750b-8b97-e9d223c0ba42", "docSlug": "88a4417a0cf1", "documentTitle": "Apellis Pharmaceuticals (APLS)", "authorId": "52_Citron_Research", "authorName": "Citron Research", "documentKindSlug": "research-note", "documentKindLabel": "Research note", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2023-11-06 00:00:00", "orientation": "portrait", "aspectRatio": 0.77295077, "pageNumber": 11, "pageCount": 13, "prevPage": 10, "nextPage": 12, "slideType": "villain_critique", "function": "expose_gap", "density": "dense", "nDataPoints": 0, "notes": "Includes two FOIA data tables as evidence of adverse events.", "elementsJson": [ "screenshot", "paragraph", "bullet_list" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/11", "deckHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42", "deckJsonHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-11", "components": [ { "bbox": null, "kind": "callout", "text": "The substantial risk of contracting Wet AMD alone warrants an FDA's decision to mandate a warning label for the drug.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-1ac1-76e9-bcda-6679594618f3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.27, "w": 0.78, "x": 0.11, "y": 0.09 }, "kind": "image", "text": "FOIA data tables", "attrs": null, "subkind": "screenshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fa3e5a90-a9ea-47a7-9609-ead73348aa6d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.78, "x": 0.11, "y": 0.79 }, "kind": "list", "text": "Benefits...according to Dr. Wykoff: Patients will not see better but Syfovre should slow the progression of the disease.", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4d6a7d90-0756-4206-bfb6-e64fd854464f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.78, "x": 0.11, "y": 0.66 }, "kind": "list", "text": "Risks...according to Dr. Wykoff: 20% likelihood of Wet AMD, extended therapy regimen, concerns regarding vasculitis.", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "805076cb-24bc-4eb1-b187-32b1b008fadc", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.78, "x": 0.11, "y": 0.88 }, "kind": "paragraph", "text": "The substantial risk of contracting Wet AMD alone warrants an FDA's decision to mandate a warning label for the drug.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4cb23fd8-a0b3-41ab-831e-472bf0ade2c1", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.49 }, "kind": "paragraph", "text": "In the presentation Dr Wykoff discusses diminution in lesion growth that according to numerous physicians, including Dr. Spaide, is statistically negligible. Despite our respect for Dr. Wykoff's perspective, his commentary would make me afraid to be a shareholder in Apellis.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8609efa3-269c-4d50-bc07-a13a09723d77", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.11, "y": 0.42 }, "kind": "paragraph", "text": "As publicized yesterday by Apellis, a presentation was made by Dr. Charles Wykoff on the “Increasing effects of Pegcetacoplan in Gale Study”. This is an add on to the two previous studies.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f3eed1b8-5f1b-47ab-af3d-0b18dc8a2f88", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.11, "y": 0.58 }, "kind": "quote", "text": "In the real world, I am using pegcetacoplan and I am a believer in anti-complement therapy. I think it's a conversation to be had with each individual patient, what the risk-benefit ratio looks like,", "attrs": null, "subkind": "pull-quote", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ef058f1b-cda4-4a8f-a365-b2c8d7aa4d55", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "In the real world, I am using pegcetacoplan and I am a believer in anti-complement therapy. I think it's a conversation to be had with each individual patient, what the risk-benefit ratio looks like, — Dr. Charles Wykoff", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-1ac1-76e9-bcda-69b1678b01b3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.65, "x": 0.11, "y": 0.38 }, "kind": "title", "text": "Recent Developments Prove Citron Theory- Gale Study", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e6bd77d1-bdc0-4801-9e85-ac592c4217e9", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 13, "from": 1, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac", "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.", "position": 1, "objective": "What are the consequences of not taking action against Syfovre's safety concerns?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }